- Home
- CTRM vs ALGS Comparison
CTRM vs ALGS Comparison
Compare CTRM & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTRM
- ALGS
- Stock Information
- Founded
- CTRM 2016
- ALGS 2018
- Country
- CTRM Cyprus
- ALGS United States
- Employees
- CTRM N/A
- ALGS 70
- Industry
- CTRM Marine Transportation
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- CTRM Consumer Discretionary
- ALGS Health Care
- Exchange
- CTRM Nasdaq
- ALGS Nasdaq
- Market Cap
- CTRM 25.0M
- ALGS 27.9M
- IPO Year
- CTRM N/A
- ALGS 2020
- Fundamental
- Price
- CTRM $2.12
- ALGS $5.36
- Analyst Decision
- CTRM
- ALGS Strong Buy
- Analyst Count
- CTRM 0
- ALGS 1
- Target Price
- CTRM N/A
- ALGS $70.00
- AVG Volume (30 Days)
- CTRM 50.1K
- ALGS 184.5K
- Earning Date
- CTRM 05-15-2025
- ALGS 05-06-2025
- Dividend Yield
- CTRM N/A
- ALGS N/A
- EPS Growth
- CTRM N/A
- ALGS N/A
- EPS
- CTRM 2.39
- ALGS N/A
- Revenue
- CTRM $76,443,340.00
- ALGS $3,945,000.00
- Revenue This Year
- CTRM N/A
- ALGS $580.86
- Revenue Next Year
- CTRM N/A
- ALGS N/A
- P/E Ratio
- CTRM $0.88
- ALGS N/A
- Revenue Growth
- CTRM N/A
- ALGS N/A
- 52 Week Low
- CTRM $1.98
- ALGS $3.76
- 52 Week High
- CTRM $5.49
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- CTRM 39.47
- ALGS 33.94
- Support Level
- CTRM $1.98
- ALGS $4.33
- Resistance Level
- CTRM $2.22
- ALGS $5.67
- Average True Range (ATR)
- CTRM 0.14
- ALGS 0.78
- MACD
- CTRM 0.01
- ALGS 0.43
- Stochastic Oscillator
- CTRM 45.16
- ALGS 49.61
About CTRM Castor Maritime Inc.
Castor Maritime Inc is a provider of seaborne transportation services for dry bulk cargo, including iron ore, coal, grain, steel products, fertilizers, cement, bauxite, sugar, and scrap metal, among others. The firm operates under two reportable segments namely Dry bulk; Aframax/LR2 tanker; Handysize tanker and Container ship. It generates maximum revenue from the Dry bulk segment.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.